Roche lung-cancer drug suffers major blow in Phase III trial

An independent committee has recommended that Roche (RHHBY) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful efficacy."

The aim of the study was to assess whether Onartuzumab, when given with the oral therapy Tarceva, helped previously treated patients live longer compared with those who just received Tarceva.

Analysts had viewed MetMab as a potential blockbuster and Roche is analyzing what the setback means for the drug's development.

Shares are -1.7% in Zurich. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs